Q: On May 23 I asked for 5iR thoughts on RX recent quarter. I see that RX does not report until May 26. So would you please hold off my request until they report. Thanks ... Cal
5i Research Answer:
EPS was 10c vs 13c last year (we do not have estimates, there is only one analyst). Revenue fell 8% to $6.4M. EBITDA fell 23% to $1.5M. RX bought back 52,800 shares in the Q1. International sales were very weak this quarter. Still, RX does expect higher growth for the full year. The balance sheet remains strong with $25M net cash. Insiders own ~14%. Not the best quarter. At 18X earnings we would consider it 'OK' but not compelling.